Methods and compositions for tumor immunotherapy using patient-derived immune cell products and il-15 superagonists

Abstract

Provided herein are methods, compositions, and kits for treating tumors by combining patient-derived immune effector cells with cytokine and therapeutic agents. In one aspect, apheresis material is processed to isolate at least two products selected from T cell, NK cell, and dendritic cell populations, which are formulated and administered to the patient. In another aspect, invariant natural killer T (iNKT) cells are expanded ex vivo using an IL-15:IL-15Rα complex and α-galactosylceramide delivered on a bacterial minicell nanoparticle, enabling scalable production of functional cells. Additional embodiments include tumor microenvironment preconditioning regimens and use of IL-15 superagonists to convert “cold” tumors into “hot” tumors.

Dependencies are inferred from the claim text.